Diabetes Tied to Higher Use of Hospital Bed-Days for Many Conditions
Medically reviewed by Drugs.com.
By Lori Solomon HealthDay Reporter
MONDAY, Aug. 7, 2023 -- Type 2 diabetes is associated with increased risks for hospital bed-days for a wide range of medical conditions, according to a study published online Aug. 4 in PLOS Medicine.
Hongjiang Wu, M.P.H., Ph.D., from the Chinese University of Hong Kong, and colleagues used data from 758,254 people with incident type 2 diabetes and matched controls without diabetes followed for a median of 7.8 years, up to 2019.
The researchers found that 60.5 percent of people with type 2 diabetes and 56.5 percent of controls had a hospital admission for any cause, with a hospital bed-day rate of 3,359 and 2,350 bed-days per 1,000 person-years, respectively. With increasing age, the all-cause hospital bed-day rate increased in controls but showed a J-shaped relationship in people with type 2 diabetes. More than one-third (38.4 percent) of bed-days in those diagnosed with diabetes before 40 years of age were caused by mental health disorders. There was an increased risk observed for a wide range of medical conditions with type 2 diabetes for all-cause hospital bed-days (relative risks, 1.75 in men and 1.87 in women); both were statistically significant. For people diagnosed with diabetes at a younger age, rate ratios were greater but varied by sex according to medical conditions.
"Health care systems and policymakers should consider allocating adequate resources and developing strategies to meet the mental health needs of young people with type 2 diabetes, including integrating mental health services into diabetes care," the authors write.
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2023
Read this next
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
Demographic, Clinical, Financial Factors Tied to GLP-1 Agonist Discontinuation
WEDNESDAY, May 29, 2024 -- Specific demographic, clinical, and financial characteristics are associated with glucagon-like peptide 1 (GLP-1) receptor agonist discontinuation...
GLP-1 Receptor Agonist Dispensing Up From 2020 to 2023 for Teens, Young Adults
WEDNESDAY, May 22, 2024 -- For adolescents and young adults, glucagon-like peptide-1 receptor agonist (GLP-1 RA) dispensing increased from 2020 to 2023, according to a research...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.